Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs Chemotherapy in Platinum-Resistant Ovarian Cancer
NCT06990503Phase 3Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Tongji Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06990503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990503.